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Abstract 
Background: High N-terminal pro-brain-type natriuretic peptide levels have been associated with a lower risk of 
type 2 diabetes mellitus (T2D). However, less is known about other cardiac stress biomarkers in this context. Here we 
evaluated the association of mid-regional pro-atrial natriuretic peptide (MR-proANP), C-terminal pro-arginine vaso-
pressin (copeptin), C-terminal pro-endothelin-1 (CT-proET-1) and mid-regional pro-adrenomedullin (MR-proADM) 
with incident T2D and changes in glucose metabolism.
Methods: We performed a prospective cohort study using data from the population-based KORA F4/FF4 study. 1773 
participants (52.3% women) with MR-proANP measurements and 960 (52.7% women) with copeptin, CT-proET-1 and 
MR-proADM measurements were included. We examined associations of circulating plasma levels of MR-proANP, 
copeptin, CT-proET-1 and MR-proADM with incident T2D, the combined endpoint of incident prediabetes/T2D and 
with fasting and 2 h-glucose, fasting insulin, HOMA-IR, HOMA-B and HbA1c at follow-up. Logistic and linear regres-
sion models adjusted for age, sex, waist circumference, height, hypertension, total/HDL cholesterol ratio, triglycerides, 
smoking, physical activity and parental history of diabetes were used to compute effect estimates.
Results: During a median follow-up time of 6.4 years (25th and 75th percentiles: 6.0 and 6.6, respectively), 119 out 
of the 1773 participants and 72 out of the 960 participants developed T2D. MR-proANP was inversely associated with 
incident T2D (odds ratio [95% confidence interval]: 0.75 [0.58; 0.96] per 1-SD increase of log MR-proANP). Copeptin 
was positively associated with incident prediabetes/T2D (1.29 [1.02; 1.63] per 1-SD increase of log copeptin). Elevated 
levels of CT-proET-1 were associated with increased HOMA-B at follow-up, while elevated MR-proADM levels were 
associated with increased fasting insulin, HOMA-IR and HOMA-B at follow-up. These associations were independent of 
previously described diabetes risk factors.
Conclusions: High plasma concentrations of MR-proANP contributed to a lower risk of incident T2D, whereas high 
plasma concentrations of copeptin were associated with an increased risk of incident prediabetes/T2D. Furthermore, 
high plasma concentrations of CT-proET-1 and MR-proADM were associated with increased insulin resistance. Our 
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Background
Type 2 diabetes mellitus (T2D) is a known major risk fac-
tor for heart failure [1], but the identification of biological 
pathways linking both diseases remains challenging. In 
recent years, several circulating biomarkers implicated in 
cardiac stress conditions have been shown to be associ-
ated with diabetes risk factors. For example, N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) and mid-
regional pro-atrial natriuretic peptide (MR-proANP) 
were inversely associated with metabolic syndrome and 
insulin resistance [2–4]. Several novel cardiac stress 
biomarkers like C-terminal pro-arginine-vasopressin 
(copeptin), C-terminal pro-endothelin-1 (CT-proET-1) 
and mid-regional pro-adrenomedullin (MR-proADM) 
were positively associated with metabolic syndrome 
and insulin resistance in cross-sectional settings [5, 6]. 
Copeptin was also associated with a family history of 
T2D in a recent study [7]. Collectively, these findings 
implicate cardiac stress biomarkers in the pathogenesis of 
T2D.
To date, a growing number of studies suggest that low 
NT-proBNP levels are associated with incident T2D 
[8–10]. Similarly, low MR-proANP levels were associated 
with incident T2D [8, 11]. Conversely, copeptin, that is 
commonly known as a biomarker for diabetes insipidus 
[12, 13], was positively associated with incident T2D in 
some studies [14–16], but others observed this positive 
association only in women [17]. In comparison to NT-
proBNP, MR-proANP and copeptin have been less widely 
investigated regarding their roles in the development of 
T2D.
Furthermore, cross-sectional studies have shown that 
levels of CT-proET-1 and MR-proADM were elevated in 
patients with T2D [5, 18], but the few existing prospec-
tive studies failed to provide evidence of their associa-
tions with incident T2D [8, 16]. However, several animal 
studies have demonstrated that high endothelin-1 but 
low adrenomedullin were involved in the development of 
insulin resistance [19, 20], suggesting that both vasoac-
tive peptides may be associated with changes in glucose 
metabolism.
The present study aimed to evaluate plasma levels of 
MR-proANP, copeptin, CT-proET-1 and MR-proADM 
for their putative associations with incident T2D, the 
combined endpoint of incident prediabetes/T2D and 
traits of glycaemia and insulin resistance (fasting and 
2  h-glucose, fasting insulin, homeostasis model assess-
ment of insulin resistance (HOMA-IR) and β-cell func-




We performed a prospective cohort study using data 
from Cooperative Health Research in the Augsburg 
Region (KORA) F4 (2006–2008) and FF4 (2013–2014) 
studies. KORA F4 and FF4 are follow-up examinations of 
the fourth survey of the population-based KORA study 
(KORA S4; 1999–2001) conducted in the South of Ger-
many. The study design has been described previously 
in detail [21]. The three examinations were carried out 
in accordance with Declaration of Helsinki, including 
obtaining written informed consent from all participants. 
The study was approved by the ethics board of the Bavar-
ian Chamber of Physicians (Munich, Germany).
This study included all persons aged 32–81 years par-
ticipating in both KORA F4 (as baseline in the present 
analysis) and KORA FF4 studies (follow-up). Baseline 
characteristics of KORA F4 participants who did not 
participate in KORA FF4 and thus were excluded from 
the current analysis are summarised in Additional file 1: 
Table  S1. Reasons for non-participation were: individu-
als had died, moved out of the study area, refused, were 
too ill/not interested/too busy to participate, or could not 
be contacted. We further excluded participants with dia-
betes at baseline, unclear diabetes status at baseline and 
follow-up, self-reported history of myocardial infarction 
and stroke, non-fasting participants prior to oral glucose 
tolerance test (OGTT) and participants with missing val-
ues on cardiac stress biomarkers or covariables.
For analysing the association with incident T2D, 1773 
nondiabetic participants at baseline (278 had predia-
betes) with MR-proANP measurements and 960 (158 
had prediabetes) with copeptin, CT-proET-1 and MR-
proADM measurements were included. For analysing 
the association with incident prediabetes/T2D, 1495 nor-
moglycaemic participants at baseline with MR-proANP 
measurements and 802 with copeptin, CT-proET-1 and 
MR-proADM measurements were included. For analys-
ing the associations with traits of glycaemia and insulin 
resistance we excluded participants who were taking 
study provides evidence that biomarkers implicated in cardiac stress are associated with incident T2D and changes in 
glucose metabolism.
Keywords: MR-proANP, Copeptin, CT-proET-1, MR-proADM, Cardiac stress biomarkers, Type 2 diabetes, Prediabetes, 
Insulin resistance, Incidence, Cohort study
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glucose-lowering medication at baseline and at follow-
up. Exclusions are described in Fig. 1 in detail.
Assessment of T2D and prediabetes
Known T2D was defined as self-reported diabetes that 
was validated through contacting the responsible phy-
sician or medical chart review or current self-reported 
use of glucose-lowering medication. Participants 
without known diabetes were assigned to receive a 
standard 75  g OGTT. Normoglycaemia was defined 
as having glucose after overnight fasting (fasting glu-
cose) < 6.1  mmol/l and 2  hours after glucose solution 
intake (2  h-glucose) < 7.8  mmol/l; prediabetes as hav-
ing fasting glucose ≥ 6.1  mmol/l but < 7.0  mmol/l and 
2  h-glucose < 7.8  mmol/l (isolated impaired fasting glu-
cose [IFG]) or fasting glucose < 6.1  mmol/l and 2  h-glu-
cose ≥ 7.8  mmol/l but < 11.1  mmol/l (isolated impaired 
glucose tolerance [IGT]) or both IFG and IGT; newly 
diagnosed diabetes as having fasting glucose ≥ 7.0 mmol/l 
or 2 h-glucose ≥ 11.1 mmol/l [21, 22].
Incident T2D was defined as having normoglycaemia 
or prediabetes at baseline and known or newly diagnosed 
T2D at follow-up. Incident prediabetes/T2D was defined 
as having normoglycaemia at baseline and prediabetes or 
known or newly diagnosed T2D at follow-up.
Laboratory measurements
During the baseline examinations in 2006–2008, blood 
samples from all participants were collected without sta-
sis and kept at 4 °C until centrifugation. All included car-
diac stress biomarkers were measured in plasma samples 
that were stored at − 80  °C until assayed. MR-proANP 
was measured in all KORA F4 study participants, while 
copeptin, CT-proET-1 and MR-proADM were meas-
ured in the first 1596 participants of the KORA F4 study. 
These biomarkers were assayed with novel sandwich 
fluoro-immunoassay (BRAHMS, Hennigsdorf, Berlin, 
Germany) using the automated system BRAHMS KRYP-
TOR. Copeptin, MR-proADM and CT-proET-1 were 
assayed simultaneously in 2010, while MR-proANP was 
assayed in 2016–2017. Intra- and inter-assay coefficients 
of variation were 3.5 and 3.4% for MR-proANP; 5.9 and 
8.9% for copeptin; 4.8 and 6.9% for CT-proET-1; 4.5 and 
7.8% for MR-proADM, respectively.
Glucose levels were measured in serum using a 
hexokinase method (GLUFlex, Dade Behring, Deerfield, 
N=1773
N=1782
KORA F4 survey (N=3080)
Exclusions:
- Participants who withdrew their participation (N=3)
- Participants who did not participate in the KORA FF4 study (follow-up); reasons: dead, moved out of study 
area, refused, too ill, not interested, too busy to participate, could not be contacted (N=916)
- Participants with prevalent or unclear diabetes status at KORA F4 (baseline): known type 2 diabetes (T2D) 
(N=115), known type 1 diabetes (N=6), OGTT newly diagnosed T2D (N=68) or unclear diabetes status due to 
missing OGTT information (N=41)
- Participants with unclear or invalid diabetes status or with other type of diabetes apart from T2D at follow-up 
(N=71) 
- Participants with history of myocardial infarction (N=32) or stroke (N=15) at baseline 
- Non-fasting participants at baseline (N=12) and at follow-up (N=2)
- Participants with missing data on covariables (N=17)
Outcome:
- Incident T2D (N=119)




- Taking antidiabetic 
medications or no information 
on antidiabetic medications 
(N=37)
- Missing values for glycaemic 










- Fasting glucose (N=1736)
- 2h-glucose (N=1715)









Participants with missing information on copeptin, CT-proET-1 
and MR-proADM measurements (N=822)
Outcome:
- Incident T2D (N=72)











- Fasting glucose (N=937)
- 2h-glucose (N=923)










- Taking antidiabetic 
medications or no information 
on antidiabetic medications 
(N=23)
- Missing values for glycaemic 
and insulin traits (N= outcome 
specific)
Further exclusion:
Participants with missing information on MR-proANP 
measurement (N=9)
Fig. 1 Flowchart showing sample sizes and reasons for exclusion
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USA) at baseline and an enzymatic colorimetric 
method on a Dimension Vista 1500 instrument (Sie-
mens Healthcare Diagnostics Inc., Newark, NJ, USA) or 
the GLUC3 assay on a Cobas c702 instrument (Roche 
Diagnostics GmbH, Mannheim, Germany) at follow-
up. Fasting insulin levels were measured in serum 
using an electrochemiluminescence immunoassay on 
a Cobas e602 instrument (Roche) at baseline and a 
solid-phase enzyme-labelled chemiluminescent immu-
nometric assay on an Immulite 2000 systems analyser 
(Siemens) or an electrochemiluminescence immunoas-
say on a Cobas e602 instrument (Roche) at follow-up. 
HOMA-IR was calculated as (fasting insulin [µU/ml] x 
fasting glucose [mmol/l])/22.5 and HOMA-B was cal-
culated as (fasting insulin [μU/ml] × 20)/(fasting glu-
cose [mmol/l] − 3.5). HbA1c at baseline was assayed in 
haemolysed whole blood using high performance liquid 
chromatography on an Adams HA 8160 Haemoglobin 
Analysis System (Arkray Inc., distributed by A. Menar-
ini Diagnostics, Florence, Italy) and at follow-up on 
Variant™ II Turbo  HbA1c Kit–2.0 (Bio-Rad Laborato-
ries Inc., Hercules, CA, USA). Calibration for different 
methods was performed as previously described [23].
Serum total cholesterol (TC) and high-density lipo-
protein (HDL) were measured with enzymatic methods 
(CHOL Flex and AHDL Flex, Dade Behring, Marburg, 
Germany) and serum triglycerides with the GPO-PAP 
method (Dade Behring). All blood parameters, except for 
2 h-glucose, were based on fasting blood samples.
Assessment of other covariables
Trained medical interviewers collected information on 
medical history, lifestyle and parental history of diabetes 
of all participants as described elsewhere [24]. Smok-
ing status was categorised into never, former or current 
smoking. Physical activity was assessed according to 
duration of leisure time sport activities with four possible 
answers: [1] > 2  h/week, [2] 1–2  h/week, [3] < 1  h/week, 
[4] none, separately in winter and in summer. A total 
score for physical activity was obtained by summing the 
possible answers in winter and in summer. Participants 
who had a total score ≥ 5 were classified as ‘physically 
inactive’, otherwise ‘physically active’. Parental history of 
diabetes was categorised into at least one parent with dia-
betes, no parent with diabetes or unknown (all remaining 
participants).
Waist circumference and height were measured 
by trained personnel as described previously [24]. 
Actual hypertension was defined as blood pres-
sure ≥ 140/90  mmHg or use of antihypertensive medi-
cation given that the participants were aware of being 
hypertensive.
Statistical analysis
Participants characteristics are reported as mean (stand-
ard deviation (SD)) or geometric mean (antilog of SD) 
for continuous variables and percentages for categori-
cal variables stratified by cases vs non-cases of incident 
T2D and of incident prediabetes/T2D. Characteristics 
between cases and non-cases were compared using anal-
ysis of variance and Chi squared test for continuous and 
categorical variables, respectively. Characteristics were 
calculated for all included participants, i.e. 1773 partici-
pants for the analysis of incident T2D and 1495 for the 
analysis of incident prediabetes/T2D.
The associations of cardiac stress biomarkers with inci-
dent T2D and incident prediabetes/T2D were analysed 
by calculating odds ratio (OR) with 95% confidence inter-
val (CI) in logistic regression models. The exact date of 
prediabetes and T2D manifestation during follow-up 
was unknown, thus we conducted logistic regression 
analysis rather than survival (time-to-event) analysis. 
Cardiac stress biomarkers were investigated as continu-
ous measures per 1-SD increase. MR-proANP, copeptin 
and MR-proADM were log-transformed to approximate 
normality. The distribution of CT-proET-1 was approxi-
mately normal and it was thus not log-transformed. All 
included cardiac stress biomarkers were z-standardized.
We performed analysis of covariance to estimate the 
associations of cardiac stress biomarkers with traits of 
glycaemia and insulin resistance at follow-up. The effect 
estimates (beta) with 95% CI were computed by assign-
ing follow-up values of the continuous traits as outcome 
variables and including the baseline values as covariables 
in the linear regression models. To approximate normal-
ity, the continuous trait variables were log-transformed 
and z-standardized.
All association analyses were adjusted for sex (male/
female), age, waist circumference, and height (all con-
tinuous) (model 1), plus actual hypertension (yes/no), 
ratio of total/HDL cholesterol (TC/HDL) (continuous), 
triglyceride concentration (continuous), smoking (cur-
rent/former/never), physical activity (inactive/active) 
and parental history of diabetes (at least one parent/
unknown/no) (model 2). We also performed sex-strati-
fied analyses and tested for interaction by sex.
Additionally, we calculated area under the receiver 
operating characteristic curve (AUC) and category-free 
net reclassification improvement (cfNRI) to quantify the 
added predictive value of the cardiac stress biomarkers 
beyond the conventional diabetes risk factors. Differences 
in AUC with 95% CI were computed using the method 
described by DeLong et al. [25]. Overall cfNRI represents 
the sum of net proportions of persons correctly assigned 
a higher predicted risk for cases  (cfNRIcases) and a lower 
predicted risk for non-cases  (cfNRInon-cases) [26]. The 
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95% CIs for cfNRIs were computed using the percentile 
bootstrap method with 1000 iterations.
All statistical analyses were performed in participants 
with complete data of baseline and follow-up measure-
ments and were conducted with SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA), except for cfNRI calcu-
lation that was conducted with R version 3.6.3 [27]. The 
P-values presented were two-tailed, and P < 0.05 was con-
sidered statistically significant.
Results
During a median follow-up time of 6.4 years (minimum: 
5.1; 25th percentile: 6.0; 75th percentile: 6.6; maximum: 
7.7), out of 1773 nondiabetic participants with MR-
proANP measurements, 119 developed T2D, and out of 
960 nondiabetic participants with copeptin, CT-proET-1 
and MR-proADM measurements, 72 developed T2D. 
Furthermore, out of 1495 normoglycaemic participants 
with MR-proANP measurement, 266 developed pre-
diabetes/T2D, and out of 802 participants with copep-
tin, CT-proET-1 and MR-proADM measurements, 145 
developed prediabetes/T2D during follow-up.
The characteristics of study participants are presented in 
Table 1. The cases (both incident T2D and incident predia-
betes/T2D) comprised more men than women. At base-
line, the cases were on average older, had a higher waist 
circumference and TC/HDL ratio, higher triglyceride con-
centrations, were more frequently hypertensive, physically 
less active and more likely to have parents with diabetes. 
The cases had higher levels of MR-proANP, copeptin, CT-
proET-1 and MR-proADM than the non-cases.
Table 1 Characteristics of study participants
Characteristics were calculated in the cohort comprising of 1773 participants for the analysis of incident T2D and 1495 for the analysis of incident prediabetes/T2D. 
Data are presented as mean (SD) or geometric mean (antilog SD) for continuous variables and as percentages for categorical variables
Italic values indicate significant P values (P < 0.05)
CT-proET-1, C-terminal pro-endothelin-1; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; SD, standard 
deviation; T2D, type 2 diabetes
a  No diabetes (normoglycaemia or prediabetes) at baseline and T2D at follow-up
b  No diabetes (normoglycaemia or prediabetes) at baseline and follow-up
c  Normoglycaemia at baseline and prediabetes or T2D at follow-up
d  Normoglycaemia at baseline and follow-up
e  Data with skewed distributions are presented as geometric mean (antilog SD)
f  Data were calculated in 960 nondiabetic participants at baseline (72 developed T2D and 888 remained nondiabetic at follow-up) and 802 normoglycaemic 
participants (145 developed prediabetes/T2D and 657 remained normoglycaemic at follow-up)










Male 56.3% 47.1% 0.052 54.5% 44.3% 0.003
Age, years 61.5 (10.8) 52.1 (11.8) < 0.001 57.1 (11.3) 50.1 (11.4) < 0.001
Waist circumference, cm 102.5 (13.0) 90.8 (13.3) < 0.001 97.3 (11.7) 88.4 (12.2) < 0.001
Height, cm 168.2 (9.4) 169.7 (9.5) 0.067 168.8 (9.5) 170.2 (9.6) 0.032
Actual hypertension 53.8% 26.5% < 0.001 42.1% 20.3% < 0.001
Parental diabetes history 0.010 < 0.001
  At least 1 parent 30.3% 23.3% 29.3% 21.4%
  Unknown 21.0% 14.2% 21.8% 12.8%
  No diabetic parents 48.7% 62.5% 48.9% 65.8%
Physically inactive 49.6% 39.3% 0.027 43.2% 37.2% 0.034
Smoking status 0.011 0.865
  Current 10.1% 17.5% 18.1% 18.4%
  Former 34.5% 40.2% 36.8% 39.6%
  Never 55.5% 42.3% 45.1% 42.0%
Ratio of total cholesterol/HDL 4.70 (1.21) 3.97 (1.14) < 0.001 4.35 (1.20) 3.83 (1.09) <  0.001
Triglycerides, mmol/le 1.57 (1.68) 1.10 (1.71) < 0.001 1.30 (1.71) 1.02 (1.67) < 0.001
MR-proANP, pmol/le 63.6 (1.7) 57.8 (1.6) 0.026 62.7 (1.6) 56.3 (1.6) < 0.001
Copeptin, pmol/le,f 6.29 (3.45) 5.19 (3.65) 0.225 7.22 (3.25) 4.93 (3.65) < 0.001
CT-proET-1, pmol/lf 48.9 (9.6) 44.4 (11.6) < 0.001 48.2 (13.6) 43.1 (10.9) < 0.001
MR-proADM, nmol/le,f 0.55 (1.24) 0.47 (1.26) < 0.001 0.52 (1.27) 0.46 (1.25) < 0.001
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Differences were also observed for traits of glycaemia 
and insulin resistance between cases and non-cases. The 
cases displayed higher levels of fasting and 2  h-glucose, 
fasting insulin, HOMA-IR, HOMA-B and HbA1c than 
the non-cases at baseline and at follow-up (Table 2).
Associations between cardiac stress biomarkers 
and incident T2D
MR-proANP was inversely associated with incident 
T2D in model 1. The OR [95% CI] was 0.70 [0.55; 0.89], 
P = 0.004 per 1-SD increase of log MR-proANP. The asso-
ciation was attenuated, but remained significant after 
additional adjustment according to model 2 (OR [95% CI] 
0.75 [0.58; 0.96], P = 0.025; Table 3). When we excluded 
participants with prediabetes at baseline the associa-
tions remained significant (OR [95% CI] 0.60 [0.37; 0.96], 
P = 0.033; Additional file 1: Table S2).
Copeptin, CT-proET-1 and MR-proADM were not 
significantly associated with incident T2D (Table  3). 
Table 2 Traits of glycaemia and insulin resistance at baseline and follow-up
Characteristics were calculated in the sample for analysing the association of cardiac stress biomarkers with glycaemic and insulin traits at the follow-up after 
excluding participants taking glucose-lowering medication. Data are presented as mean (SD) or geometric mean (antilog SD)
Italic values indicate significant P values (P < 0.05)
HbA1c, haemoglobin A1c; HOMA-B, homeostasis model assessment of beta-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; SD, standard 
deviation; T2D, type 2 diabetes
a  No diabetes (normoglycaemia or prediabetes) at baseline and T2D at follow-up
b  No diabetes (normoglycaemia or prediabetes) at baseline and follow-up
c  Normoglycaemia at baseline and prediabetes or T2D at follow-up
d  Normoglycaemia at baseline and follow-up
e  Data with skewed distributions are presented as geometric mean (antilog SD)
f  Data were calculated in 1736 nondiabetic participants at baseline (84 developed T2D and 1652 remained nondiabetic) and 1484 normoglycaemic participants (257 
developed prediabetes/T2D and 1227 remained normoglycaemic at follow-up)
g  Data were calculated in 1715 nondiabetic participants at baseline (63 developed T2D and 1652 remained nondiabetic) and 1478 normoglycaemic participants (251 
developed prediabetes/T2D and 1227 remained normoglycaemic at follow-up)
h  Data were calculated in 1735 nondiabetic participants at baseline (84 developed T2D and 1651 remained nondiabetic) and 1484 normoglycaemic participants (257 
developed prediabetes/T2D and 1227 remained normoglycaemic at follow-up)
i  Data were calculated in 1731 nondiabetic participants at baseline (84 developed T2D and 1647 remained nondiabetic) and 1479 normoglycaemic participants (256 
developed prediabetes/T2D and 1223 remained normoglycaemic at follow-up)
Incident T2D Incident prediabetes/T2D
Casesa Non-casesb P Casesc Non-casesd P
Measurements at baseline
  Fasting serum glucose, mmol/le,f 5.78 (1.09) 5.12 (1.10) < 0.001 5.38 (1.07) 5.01 (1.08) < 0.001
  2 h serum glucose, mmol/le,g 7.89 (1.23) 5.51 (1.29) < 0.001 6.04 (1.20) 5.12 (1.25) < 0.001
  Fasting serum insulin, µU/mle,h 13.46 (1.66) 8.14 (1.63) < 0.001 9.98 (1.64) 7.46 (1.57) < 0.001
  HOMA-IRe,h 3.46 (1.71) 1.85 (1.70) < 0.001 2.39 (1.68) 1.66 (1.62) < 0.001
  HOMA-Be,h 119.9 (1.7) 103.8 (1.6) 0.004 107.6 (1.6) 101.9 (1.5) 0.073
  HbA1c, mmol/moli 39.1 (3.5) 35.1 (3.5) < 0.001 36.9 (3.2) 34.4 (3.3) < 0.001
Measurements at follow-up
  Fasting serum glucose, mmol/le,f 6.82 (1.22) 5.35 (1.10) < 0.001 5.93 (1.12) 5.20 (1.08) < 0.001
  2h serum glucose, mmol/le,g 11.75 (1.31) 5.73 (1.31) < 0.001 8.02 (1.25) 5.19 (1.24) <  0.001
  Fasting serum insulin, µU/mle,h 15.18 (1.69) 8.65 (1.73) < 0.001 12.62 (1.72) 7.71 (1.66) < 0.001
  HOMA-IRe,h 4.60 (1.87) 2.06 (1.82) < 0.001 3.33 (1.79) 1.78 (1.71) < 0.001
  HOMA-Be,h 95.0 (1.7) 96.0 (1.7) 0.864 106.2 (1.7) 92.5 (1.6) < 0.001
  HbA1c, mmol/moli 43.2 (9.3) 35.2 (3.8) < 0.001 37.8 (4.8) 34.6 (3.5) < 0.001
Table 3 Associations between  cardiac stress biomarkers 
and incident type 2 diabetes
ORs [95% CI] were calculated per 1-SD increment of cardiac stress biomarkers
Model 1: adjusted for age, sex, waist circumference and height
Model 2: Model 1 + actual hypertension, ratio of total cholesterol and HDL, 
triglycerides, smoking status, physical activity and parental history of diabetes
Italic values indicate significant P values (P < 0.05)
CI, confidence interval; CT-proET-1, C-terminal pro-endothelin-1; MR-proADM, 
mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial 
natriuretic peptide; OR, odds ratio; SD, standard deviation
Biomarkers Ncases/non-cases Model OR [95% CI] P
MR-proANP 119/1645 Model 1 0.70 [0.55; 0.89] 0.004
Model 2 0.75 [0.58; 0.96] 0.025
Copeptin 72/888 Model 1 1.03 [0.78; 1.36] 0.824
Model 2 1.05 [0.79; 1.40] 0.730
CT-proET-1 72/888 Model 1 0.93 [0.69; 1.25] 0.626
Model 2 0.82 [0.59; 1.14] 0.234
MR-proADM 72/888 Model 1 0.87 [0.62; 1.20] 0.389
Model 2 0.85 [0.59; 1.21] 0.358
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Sex-specific associations between the cardiac stress bio-
markers and incident T2D are presented in Additional 
file 1: Table S3.
The AUC [95% CI] of conventional T2D risk factors 
(model 2) without any cardiac stress biomarkers predict-
ing incident T2D in the full study population was 0.833 
[0.799; 0.867] and 0.853 [0.814; 0.891] in the subpopu-
lation with copeptin, CT-proET-1 and MR-proADM 
measurements. None of the cardiac stress biomarkers 
individually improved the AUC significantly on top of 
model 2 (Additional file  1: Table  S4). The overall cfNRI 
was significantly improved when MR-proANP was 
added to model 2  (cfNRIoverall [95% CI] 0.211 [0.015; 
0.466]), but cfNRI for cases and non-cases were not sig-
nificantly improved  (cfNRIcases [95% CI] 0.109 [− 0.018; 
0.273] and  cfNRInon-cases [95% CI] 0.102 [− 0.009; 0.231]). 
None of the other cardiac stress biomarkers significantly 
improved the cfNRI when added to model 2 (Additional 
file 1: Table S4).
Associations between cardiac stress biomarkers 
and incident prediabetes/T2D
Copeptin was positively associated with incident pre-
diabetes/T2D. The OR [95% CI] was 1.30 [1.03; 1.63], 
P = 0.027 per 1-SD increase of log copeptin in model 1. 
The association remained similar after further adjust-
ment according to model 2 (OR [95% CI] 1.29 [1.02; 
1.63], P = 0.033; Table 4). In a sensitivity analysis exclud-
ing participants who progressed from normoglycaemia at 
baseline to T2D at follow-up, copeptin was also positively 
associated with incident prediabetes alone (OR [95% CI] 
1.43 [1.10; 1.86], P = 0.008; Additional file 1: Table S2).
We observed no significant associations of MR-
proANP, CT-proET-1 and MR-proADM with incident 
prediabetes/T2D (Table  4). Sex-specific associations 
between the cardiac stress biomarkers and incident pre-
diabetes/T2D are presented in Additional file 1: Table S5.
The AUC [95% CI] of the conventional T2D risk factors 
(model 2) predicting incident prediabetes/T2D without 
any cardiac stress biomarkers was 0.779 [0.750; 0.807] in 
the total study population and 0.796 [0.760; 0.832] in the 
subpopulation with available copeptin, CT-proET-1 and 
MR-proADM measurements. The addition of the cardiac 
stress biomarkers individually to model 2 did not signifi-
cantly improve the AUC and overall cfNRI (Additional 
file 1: Table S6).
Associations of cardiac stress biomarkers with traits 
of glycaemia and insulin resistance at follow-up
Elevated MR-proANP levels were only significantly asso-
ciated with reduced HbA1c in model 1, but the asso-
ciation was attenuated to non-significance after further 
adjustment in model 2 (Fig.  2). Copeptin was not sig-
nificantly associated with any of the assessed continuous 
traits at follow-up.
Elevated levels of CT-proET-1 and MR-proADM at 
baseline were significantly associated with higher fast-
ing insulin and HOMA-B at follow-up in model 1. 
Elevated MR-proADM levels were also significantly asso-
ciated with higher 2 h-glucose and HOMA-IR in model 
1 (Fig. 2, model 1). Further adjustment (model 2) attenu-
ated the positive association between CT-proET-1 and 
fasting insulin and also the positive association between 
MR-proADM and 2 h-glucose to non-significance (Fig. 2, 
model 2). Additionally, we observed significant inverse 
associations of CT-proET-1 and MR-proADM with 
HbA1c, even after further adjustment in model 2.
Discussion
In the current study elevated MR-proANP levels were 
associated with a lower risk of incident T2D, elevated 
copeptin levels were associated with a higher risk of inci-
dent prediabetes/T2D, and elevated CT-proET-1 and 
MR-proADM levels were associated with increases in 
several traits of insulin resistance during the follow-up 
period. Overall, the examined cardiac stress biomarkers 
did not substantially improve the prediction of incident 
T2D and incident prediabetes/T2D when added to the 
models containing conventional diabetes risk factors. 
As previous research demonstrated, the predictive abil-
ity of established diabetes risk scores is rarely consider-
ably improved by the addition of single novel biomarkers, 
Table 4 Associations between  cardiac stress biomarkers 
and  the  combined incident prediabetes/type 2 diabetes 
endpoint
ORs [95% CI] were calculated per 1-SD increment of cardiac stress biomarkers
Model 1: adjusted for age, sex, waist circumference and height
Model 2: Model 1 + actual hypertension, ratio of total cholesterol and HDL, 
triglycerides, smoking status, physical activity and parental history of diabetes
Italic values indicate significant P values (P < 0.05)
CI, confidence interval; CT-proET-1, C-terminal pro-endothelin-1; MR-proADM, 
mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial 
natriuretic peptide; OR, odds ratio; SD, standard deviation
Biomarkers Ncases/non-cases Model OR [95% CI] P
MR-proANP 266/1229 Model 1 0.91 [0.76; 1.09] 0.297
Model 2 0.94 [0.78; 1.14] 0.539
Copeptin 145/657 Model 1 1.30 [1.03; 1.64] 0.027
Model 2 1.29 [1.02; 1.63] 0.033
CT-proET-1 145/657 Model 1 1.15 [0.95; 1.40] 0.154
Model 2 1.15 [0.94; 1.41] 0.169
MR-proADM 145/657 Model 1 1.09 [0.85; 1.38] 0.497
Model 2 1.08 [0.84; 1.39] 0.543
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however, this does not preclude relevant associations 
between the biomarkers and T2D [28].
MR-proANP and incident T2D
Our results describing the inverse association of MR-
proANP with incident T2D are consistent with results 
from previous studies [8, 11]. Additionally, we observed 
a significant improvement of overall cfNRI but not 
AUC in predicting incident T2D after the addition of 
MR-proANP to model 2. This may be explained by the 
fact that the cfNRI is more sensitive to small changes in 
predicted risk after the addition of a new marker than 
the AUC [29]. We are not aware of any other studies 
addressing improvement in T2D prediction by the 
addition of MR-proANP.
Furthermore, our study adds evidence that higher 
MR-proANP levels were associated with decreased 
HbA1c at follow-up in a model adjusted for age, 
sex, waist circumference and height. However, fur-
ther adjustment attenuated this association to 
non-significance.
Low atrial natriuretic peptide (ANP) levels were asso-
ciated with the activation of the renin-angiotensin sys-
tem [30], which in turn could promote the development 
of insulin resistance and thus T2D [31]. However, in the 
present study we observed no significant associations of 
Fig. 2 Associations of cardiac stress biomarkers with continuous traits of glycaemia and insulin resistance at follow-up. Thick plots show significant 
associations. The analyses were adjusted for baseline value of glycaemic or insulin traits, age, sex, waist circumference and height (model 1) and 
were further adjusted for actual hypertension, ratio of total cholesterol and HDL, triglycerides, smoking status, physical activity and parental 
history of diabetes (model 2). Abbreviations: 2 hG, 2 h-glucose; A1c, haemoglobin A1c; beta, homeostasis model assessment of beta-cell function; 
CT-proET-1, C-terminal pro-endothelin-1; FG, fasting glucose; FI, fasting insulin; IR, homeostasis model assessment of insulin resistance; MR-proADM, 
mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide
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baseline MR-proANP with any of the assessed insulin 
traits at follow-up. By contrast, a recent investigation 
from the MDC study [32] among 2243 nondiabetic par-
ticipants who were followed up for 16.5 years reported 
a significant inverse association of MR-proANP with 
fasting insulin and HOMA-IR at follow-up. However, 
the authors reported no significant associations of MR-
proANP with fasting and 2  h-glucose at follow-up as 
seen in our results.
Findings from experimental studies suggest that natriu-
retic peptides directly affect metabolism in skeletal mus-
cle and adipose tissue. Natriuretic peptides were shown 
to induce fat oxidative capacity, reduce lipotoxicity and 
enhance insulin signalling in skeletal muscle and promote 
lipolysis, browning and glucose uptake in adipose tissue 
[33]. ANP also inhibited the secretion of adipokines and 
cytokines involved in inflammation and insulin resist-
ance [34]. These biological effects of ANP improved insu-
lin sensitivity and blood glucose control [33] and may 
thereby explain the inverse association of MR-proANP 
and incident T2D.
Copeptin and incident prediabetes/T2D
Our findings on the positive association between copep-
tin and incident prediabetes/T2D among normogly-
caemic participants at baseline are in accordance with 
findings from the DESIR study [15] showing a positive 
association between copeptin and incident IFG/T2D 
among participants with normal fasting glucose at base-
line. However, in the present study, copeptin was not 
significantly associated with incident T2D among nondi-
abetic participants at baseline. Similar to our finding, the 
FINRISK study [8] also observed no significant associa-
tions between copeptin and incident T2D among nondia-
betic participants at baseline. In contrast, investigations 
from the MDC study [14] and the British Regional Heart 
Study [35] reported positive associations between copep-
tin and incident T2D among nondiabetic participants 
at baseline. These associations were stronger in partici-
pants without IFG than in all nondiabetic participants at 
baseline. Recently, higher copeptin levels were reported 
in participants with prediabetes than in participants with 
T2D [7]. This finding corroborates our results on a more 
pronounced association of copeptin with incident pre-
diabetes alone than with the combined incident predia-
betes/T2D. Unfortunately, our study is underpowered to 
examine the association between copeptin and incident 
T2D alone among participants with normoglycaemia at 
baseline.
Previously, elevated copeptin was reported to be associ-
ated with increased insulin resistance [14, 15] which may 
partly explain our findings. Of note, we also observed a 
trend towards a positive association of copeptin with 
fasting insulin and HOMA-IR. The active peptide argi-
nine vasopressin directly stimulates glucagon and insulin 
release from pancreas and induces hepatic glycogenoly-
sis [36]. Interestingly, higher rather than lower copeptin 
levels were reported in participants treated with empa-
gliflozin, which is known to reduce hyperglycaemia, than 
in participants treated with placebo [37]. Although this 
finding might be due to a mild volume depletion caused 
by sodium-glucose cotransporter-2 inhibition of empa-
gliflozin [37], further studies are needed to understand 
the mechanism of copeptin-induced hyperglycaemia.
The utility of copeptin in the prediction of prediabetes/
T2D is not widely understood. In the present analysis, 
we did not observe a significantly improved prediction of 
incident prediabetes/T2D after the addition of copeptin 
to models containing conventional diabetes risk factors. 
However, Abbasi et  al. [17] shows that copeptin signifi-
cantly improved the prediction of T2D in addition to 
conventional diabetes risk factors in women, but not in 
men. More studies are needed to understand the clinical 
significance of copeptin in the prediction of prediabetes/
T2D beyond the known role of predicting clinical out-
comes of heart failure [38] and other major cardiovascu-
lar events in T2D patients [39].
CT-proET-1, MR-proADM and insulin resistance
In the present study we also observed positive associa-
tions of CT-proET-1 and MR-proADM with increased 
traits of insulin resistance during follow-up in nondia-
betic participants. Our findings extend findings from 
previous cross-sectional analyses demonstrating that 
CT-proET-1 and MR-proADM were positively associated 
with metabolic risk factors and insulin resistance [5, 40, 
41]. To the best of our knowledge, this is the first study 
to examine the prospective associations of CT-proET-1 
and MR-proADM with fasting insulin, HOMA-IR and 
HOMA-B in a nondiabetic population.
Several in  vitro and experimental studies have shown 
that endothelin-1 stimulated insulin secretion directly 
from pancreas [19, 42]. Endothelin-1 also limited insu-
lin action [43] and decreased adiponectin mRNA levels 
in adipocytes [44]. These biological effects may lead to 
the development of insulin resistance and thus, sup-
port our findings. The positive association between CT-
proET-1 with higher HOMA-B at follow-up in our study 
was most likely a consequence of its positive association 
with insulin resistance. Furthermore, there is evidence 
that endothelin-1 inhibits glucose uptake in human skel-
etal muscle [45] that may further explain the trend of a 
positive association between CT-proET-1 and 2  h-glu-
cose at follow-up in our study as 2  h-glucose mainly 
reflects muscle glucose uptake [46]. Interestingly, we also 
observed an inverse association between CT-proET-1 
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and HbA1c. The reason for this finding is still unknown 
and further confirmation is needed.
Regarding the association between MR-proADM and 
insulin resistance, we found that higher MR-proADM 
levels were positively rather than inversely associated 
with fasting insulin, HOMA-IR and HOMA-B at fol-
low-up. Our findings are contradictory to the results 
of a previous animal study [20]. The mechanistic evi-
dence linking MR-proADM and insulin resistance is 
not well understood and controversial. In the previous 
animal study [20] adrenomedullin deficiency increased 
oxidative stress and induced insulin resistance. Adre-
nomedullin also inhibited insulin secretion on the 
pancreatic islets and reduced insulin levels accom-
panied by an increase in postprandial glucose [47]. 
In contrast, high adrenomedullin levels stimulated 
interleukin-6 and remarkably potentiated stimulatory 
effects of tumor necrosis factor-α, interleukin-1β and 
lipopolysaccharide that contribute to the development 
of insulin resistance [48]. A recent epidemiological 
study further demonstrated that high MR-proADM 
was associated with increased BMI and waist circum-
ference at follow-up [49]. The study also reported that 
high MR-proADM was associated with lower fasting 
glucose levels that contradicts evidence from the ani-
mal models [47]. More studies are needed to confirm 
our findings on the associations between high MR-
proADM and increased insulin resistance at follow-up.
Strengths and limitations
Strengths of the current study include the prospec-
tive study design, the population-based sample and the 
availability of OGTT data at baseline and follow-up. 
This enabled us to examine prospective associations 
between the included cardiac stress biomarkers with 
progression from normoglycaemia to prediabetes/T2D 
and with the continuous traits of glycaemia and insulin 
resistance at follow-up.
Limitations of this study are: Our study has a rela-
tively low number of incident T2D cases and is there-
fore not sufficiently powered to examine associations 
with incident T2D among participants with normo-
glycaemia and prediabetes at baseline separately. Fur-
thermore, participants who participated in KORA FF4 
tended to be healthier than those who did not partici-
pate, which could have introduced some selection bias. 
Due to the lack of data on history of heart failure at 
baseline, we were unable to exclude participants with 
heart failure. Due to the lack of follow-up data on the 
included cardiac stress biomarkers, we were also una-
ble to examine changes of the biomarkers in the pro-
gression towards diabetes. Our study participants were 
predominantly European descent, which means that 
further studies need to confirm our findings in other 
ethnic groups.
Conclusions
High plasma concentrations of MR-proANP were asso-
ciated with a lower risk of incident T2D, whereas high 
plasma concentrations of copeptin were associated with 
an increased risk of incident prediabetes/T2D. Further-
more, high plasma concentrations of CT-proET-1 and 
MR-proADM were associated with increased insulin 
resistance during follow-up time. Our study provides 
evidence that biomarkers implicated in cardiac stress 
are associated with incident T2D and changes in glucose 
metabolism.
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